Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 15;13(9):10863-10870.
eCollection 2021.

Comparison of pyrotinib or lapatinib with chemotherapy for patients with HER2 positive breast cancer after first-line treatment failure: a retrospective study

Huihui Yang  1 , Wei Wang  2
Affiliations

Comparison of pyrotinib or lapatinib with chemotherapy for patients with HER2 positive breast cancer after first-line treatment failure: a retrospective study

Huihui Yang et al. Am J Transl Res. .

Abstract

Objective: To explore the difference in efficacy and safety of pyrotinib or lapatinib combined with chemotherapy in human epidermal growth factor receptor-2 (HER-2) positive breast cancer patients who failed the first-line trastuzumab-containing treatment.

Methods: The present retrospective study included 164 HER-2 positive breast cancer patients admitted to our hospital. Among them, 68 cases received pyrotinib combined with chemotherapy after the failure of trastuzumab first-line treatment (pyrotinib group), and the other 96 cases received lapatinib combined chemotherapy (lapatinib group). The end of the follow-up time was set as June 1, 2020. The primary endpoint was progression free survival (PFS), and the secondary endpoints included best objective response rate (ORR) and safety.

Results: Till the end of the follow-up, the best ORR (60.3% vs. 34.4%) in the pyrotinib group was significantly higher than that in the lapatinib group, and the median PFS (9.0 months vs. 6.2 months) was also largely prolonged (P<0.01). In addition, the median PFS of the patients with brain metastases in the pyrotinib group was 6.5 months, and was much longer that in the lapatinib group which wereth 3.5 months in length (P<0.05). Multivariate COX regression analysis showed that pyrotinib combined with chemotherapy (HR=0.653, P<0.05) was associated with longer PFS of patients, while the lapatinib group had a higher proportion of vomiting and hand foot syndrome than the pyrotinib group (P<0.05).

Conclusion: After the failure of first-line trastuzumab-containing treatment, combination of pyrotinib with chemotherapy has more significant short-term efficacy in HER-2 positive breast cancer patients than lapatinib combined with chemotherapy, especially in patients with brain metastasis.

Keywords: Pyrotinib; breast cancer; human epidermal growth factor receptor-2; safety; trastuzumab.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Kaplan-Meier curve of PFS in patients of two groups. PFS: progression free survival.
Figure 2
Figure 2
PFS subgroup analysis of patients in two groups. A: Kaplan-Meier curve of PFS in patients with midbrain metastasis in two groups (χ 2=4.692, Log-rank P=0.030); B: Kaplan-Meier curve of PFS in patients treated with trastuzumab for more than 6 months in both groups (χ 2=4.579, Log-rank P=0.033). PFS: progression free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Macpherson IR, Spiliopoulou P, Rafii S, Saggese M, Baird RD, Garcia-Corbacho J, Italiano A, Bonneterre J, Campone M, Cresti N, Posner J, Takeda Y, Arimura A, Spicer J. A Phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Res. 2019;22:1. - PMC - PubMed
    1. Squires H, Stevenson M, Simpson E, Harvey R, Stevens J. Trastuzumab emtansine for treating her2-positive, unresectable, locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2016;34:673–680. - PubMed
    1. Lu X, Ma J, Chu J, Shao Q, Zhang Y, Lu G, Li J, Huang X, Li W, Li Y, Ling Y, Zhao T. MiR-129-5p sensitizes the response of Her-2 positive breast cancer to trastuzumab by reducing Rps6. Cell Physiol Biochem. 2017;44:2346–2356. - PubMed
    1. Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T. A randomized phase ii trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Breast. 2018;40:67–75. - PubMed
    1. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–1791. - PMC - PubMed

LinkOut - more resources